米卡芬净和伏立康唑在健康成人中单独给药及联合给药后的稳态药代动力学。
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
作者信息
Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A
机构信息
Astellas Pharma US, Inc., 3 Parkway North, Deerfield, IL 60015-2548, USA.
出版信息
Antimicrob Agents Chemother. 2007 Feb;51(2):787-90. doi: 10.1128/AAC.00673-06. Epub 2006 Nov 20.
Abstract
We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.
摘要
我们评估了35名志愿者中稳态米卡芬净（麦考酚酯）或安慰剂与稳态伏立康唑的药代动力学及相互作用。米卡芬净药代动力学参数和安慰剂校正后伏立康唑药代动力学参数的最小二乘均值比的90%置信区间在80%至125%范围内，表明不存在药物相互作用。
相似文献
1
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
Antimicrob Agents Chemother. 2007 Feb;51(2):787-90. doi: 10.1128/AAC.00673-06. Epub 2006 Nov 20.
2
Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.
J Clin Pharmacol. 2005 Sep;45(9):1018-24. doi: 10.1177/0091270005279274.
3
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
J Clin Pharmacol. 2005 Dec;45(12):1373-82. doi: 10.1177/0091270005281234.
4
Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.
J Clin Pharmacol. 2005 Aug;45(8):954-60. doi: 10.1177/0091270005278601.
5
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Antimicrob Agents Chemother. 2001 Dec;45(12):3322-7. doi: 10.1128/AAC.45.12.3322-3327.2001.
6
Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
J Clin Pharmacol. 2005 Oct;45(10):1145-52. doi: 10.1177/0091270005279580.
7
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
Pediatr Infect Dis J. 2006 Dec;25(12):1110-5. doi: 10.1097/01.inf.0000245103.07614.e1.
8
Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
J Clin Pharmacol. 2002 Apr;42(4):395-402.
9
Clinical pharmacokinetics of voriconazole.
Int J Antimicrob Agents. 2006 Apr;27(4):274-84. doi: 10.1016/j.ijantimicag.2006.01.003. Epub 2006 Mar 24.
10
Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
J Vet Pharmacol Ther. 2009 Jun;32(3):235-40. doi: 10.1111/j.1365-2885.2008.01030.x.
引用本文的文献
1
Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
J Clin Pharm Ther. 2020 Dec;45(6):1207-1217. doi: 10.1111/jcpt.13211. Epub 2020 Jul 16.
2
Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.
Eur J Clin Pharmacol. 2020 May;76(5):695-702. doi: 10.1007/s00228-020-02840-0. Epub 2020 Feb 11.
3
Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.
Rev Esp Quimioter. 2020 Feb;33(1):44-48. doi: 10.37201/req/067.2019. Epub 2019 Dec 23.
4
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Clin Pharmacokinet. 2020 Jun;59(6):781-808. doi: 10.1007/s40262-019-00856-z.
5
Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis.
Sci Rep. 2019 Jun 27;9(1):9331. doi: 10.1038/s41598-019-45776-x.
6
Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02528-17. Print 2018 Jun.
7
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.
Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5.
8
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9. doi: 10.1128/AAC.00623-15. Epub 2015 May 11.
9
Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.
Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):285-93. doi: 10.1007/s13318-014-0204-y. Epub 2014 Jun 3.
10
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.
Infect Drug Resist. 2008;1:63-77. Epub 2009 Jan 12.
本文引用的文献
1
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
J Clin Pharmacol. 2005 Dec;45(12):1373-82. doi: 10.1177/0091270005281234.
2
No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):62-8. doi: 10.1046/j.1365-2125.2003.02001.x.
3
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):30-6. doi: 10.1046/j.1365-2125.2003.01996.x.
4
Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):17-23. doi: 10.1046/j.1365-2125.2003.01994.x.
5
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):10-6. doi: 10.1046/j.1365-2125.2003.01993.x.
6
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
J Infect Dis. 2003 Jun 15;187(12):1834-43. doi: 10.1086/375420. Epub 2003 Jun 4.
7
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69. doi: 10.1128/AAC.46.6.1857-1869.2002.
8
Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
J Antibiot (Tokyo). 2002 Feb;55(2):219-22. doi: 10.7164/antibiotics.55.219.
9
In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
J Antimicrob Chemother. 2000 Sep;46(3):485-7. doi: 10.1093/jac/46.3.485.
10
Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Antimicrob Agents Chemother. 2000 Jun;44(6):1728-30. doi: 10.1128/AAC.44.6.1728-1730.2000.
Zotero 插件